Grant Seeger, MD
Radiation Oncology · Grand Forks, NDNPI 1427252014
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (33.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Accuray Incorporated at 50.0% of the total. Reporting peaked in 2023 at $14,275 and has fallen 78.5% since, to $3,076 in 2025. Among radiation oncology clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $255.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Accuray Incorporated$15K
- Pfizer$5K
- Merck$3K
- Telix Pharmaceuticals$2K
- Varian Medical Systems, Inc.$1K
- Siemens Medical Solutions USA, Inc.$1K
- plus $3K from 19 others
Across 8 payments — averaging $51,146 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$214K
- Merck$159K
- Sumitomo Pharma America, Inc.$37K
What the payments were for
- Consulting fees$7,50024%
- Speaking & faculty fees$10,21233%
- Travel & lodging$5,64918%
- Food & beverage$7,59925%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Accuray Incorporated | 26 | $15,467 |
| Pfizer | 5 | $5,141 |
| Merck | 17 | $2,634 |
| Telix Pharmaceuticals | 6 | $2,048 |
| Varian Medical Systems, Inc. | 7 | $1,134 |
| Siemens Medical Solutions USA, Inc. | 8 | $1,084 |
| Novocure Inc. | 8 | $643 |
| AstraZeneca | 8 | $380 |
| Reflexion Medical, Inc. | 2 | $357 |
| Elekta, Inc. | 4 | $341 |
| Tempus AI, Inc | 3 | $302 |
| Palette Life Sciences, Inc. | 4 | $267 |
| Boston Scientific | 5 | $266 |
| GE HealthCare | 5 | $148 |
| Janssen Scientific Affairs, LLC | 2 | $120 |
| Zap Surgical Systems, Inc. | 1 | $116 |
| Veran Medical Technologies, Inc. | 2 | $110 |
| Brainlab, Inc. | 1 | $90 |
| Novartis | 1 | $69 |
| Stemline Therapeutics Inc. | 1 | $67 |
| Northern X-ray Company | 1 | $66 |
| Stryker | 1 | $38 |
| Genentech USA, Inc. | 1 | $33 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tomo Therapy System$8,157
- TomoTherapy System$6,713
- ORGOVYX$5,141
- ILLUCCIX$1,969
- TrueBeam$1,199
- REFLEXION MEDICAL RADIOTHERAPY SYSTEM$357
- SOMATOM go.Top$206
- Symbia Intevo Bold$206
- ARIA Radiation Therapy Management Software$168
- CyberKnife System$157
- ELEKTA MEDICAL LINEAR ACCELERATOR$145
- XT CDX$124
- SOMATOM Edge Plus$124
- ZAP-X MV IMAGER$116
- ZAP-X TREATMENT PLANNING SOFTWARE$116
- ZAP-X TREATMENT DELIVERY SOFTWARE$116
- ZAP-X RADIOSURGERY SYSTEM$116
- OPTUNE LUA (NOVOTTF-200T)$111
- Optune Gio$107
How this compares
$30,960 in reported general payments places this provider in the 90th percentile of 20 radiation oncology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 14 | $36,813 |
| Bicalutamide | 34 | $637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $18 | $36,81314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 radiation oncology providers in North Dakota.
Other radiation oncology in Grand Forks
- William NoyesGrand Forks$1.9M
- Marshall WinchesterGrand Forks$0
- Jacob WynneGrand Forks$0
- Robert ReynoldsBismarck$2K
- Joon LeeBismarck$1K
- Michael GrantMinot$1K
- Salah DajaniFargo$508
- Jason HirshbergMinot$290
- Sommer NurkicFargo$216
- Elliot LawrenceFargo$157
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.